Weight-Loss drugs may worsen muscle loss in seniors – can exercise save it?
NCT ID NCT07104539
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a 14-week strength training program can prevent muscle loss and balance problems in adults aged 50 and older who are starting GLP-1 medications like Wegovy or Zepbound. Thirty participants will either start strength training right away or wait 14 weeks before beginning. Researchers will measure changes in muscle mass, walking speed, and balance recovery. The goal is to understand how exercise might offset the muscle-related risks of these popular weight-loss drugs.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Strength training (resistance exercises supervised by a trainer)
- What this could lead to
- If successful, this could show that strength training helps preserve muscle mass and balance in older adults using GLP-1 medications for weight loss.
- What could go wrong
- This is a small, early-stage study with only 30 participants. It is designed to gather knowledge, not to prove a treatment works. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age, 50y+ * Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less * Weight \<300 lb * Pass a health and exercise readiness screening Exclusion Criteria: * Age \<50 * Weight \>300 lb * Osteoporosis * Active metabolic, neoplastic, or cardiovascular disease * Unable or unwilling to provide consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Muscle mass are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Virginia Tech
RECRUITINGBlacksburg, Virginia, 24061, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common diabetes drug weaken or protect aging muscles?
- Shocking gains? study tests electric boost for weightlifters
- Protein drink may help seniors regain strength and independence
- Vitamin d pills tested as muscle saver for seniors with obesity
- Could more protein keep dialysis patients healthier?
- Could weak muscles mean higher bleeding risk for seniors on blood thinners?